Hologic hits 52-week high

Shares of the maker of medical equipment rose 7% to 22.36 after an interim analysis of 12,631 mammograms found that those using a combination of 3D and 2D had a 27% better detection rate and a 15% lower false-positive rate than those using 2D alone. Hologic (HOLX) sells a 3D system called Selenia, and the new study should help it in reimbursement negotiations with Medicare and Medicaid, according to ISI Group analysts.

Advertisement